AC
UTHR icon

Athanor Capital’s United Therapeutics UTHR Stock Holding History

Athanor Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,969
Closed -$1.33M – 771
2021
Q1 		$1.33M Sell
7,969
-45
-0.6% -$7.5K 0.03% 283
2020
Q4 		$1.22M Buy
+8,014
New +$1.05M 0.03% 265

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Athanor Capital's UTHR Position: Q2 2021 in Review

Athanor Capital sold out of United Therapeutics (UTHR) in Q2 2021, closing a stake of 7,969 shares — an estimated $1.33M sold.

Athanor Capital first reported a position in UTHR in Q4 2020 and held it in 2 quarters. The position peaked at $1.33M in Q1 2021. 403 funds tracked by Wall St. Rank hold UTHR as of Q2 2021.

  • Athanor Capital reported no remaining United Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 7,969 United Therapeutics shares in Q2 2021, an estimated $1.33M.
  • Athanor Capital first reported a position in United Therapeutics in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's United Therapeutics position peaked at $1.33M in Q1 2021.
  • 403 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.